Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 19/20 | 0.52 |
| ▸ | CTSL | P07711 | 15/20 | 0.52 |
| ▸ | CTSS | P25774 | 15/20 | 0.52 |
| ▸ | CTSB | P07858 | 5/20 | 0.52 |
| ▸ | CTSV | O60911 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5983508 | 1.00 | CTSK (0.52) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL5983410 | 0.88 | CTSK (0.58) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL5983402 | 0.88 | CTSK (0.58) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL5982895 | 0.85 | CTSK (0.59) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL5982907 | 0.85 | CTSK (0.59) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL5983115 | 0.83 | CTSK (0.53) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL5983102 | 0.83 | CTSK (0.53) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL5983387 | 0.83 | CTSK (0.55) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL5983381 | 0.83 | CTSK (0.55) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL5983311 | 0.81 | CTSK (0.48) | CTSKCTSLCTSSCTSBCTSV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060052365-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2006-03-09 | — | — | US | claimed |
| JP-2006505526-A | — | — | 2006-02-16 | — | — | JP | claimed |
| EP-1539178-A2 | PROTEASE INHIBITORS | SmithKline Beecham Corporation (US) | 2005-06-15 | — | — | EP | claimed |
| WO-2004017911-A2 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-03-04 | — | — | WO | claimed |
| US-20060052365-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2006-03-09 | — | — | US | disclosed |
| EP-1539178-A2 | PROTEASE INHIBITORS | SmithKline Beecham Corporation (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004017911-A2 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052365-A1 | Protease inhibitors | CTSS, CTSE, CMA1 | CTSK 5/4885CTSL 12/4885CTSS 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.